Catalent Pharma Solutions, Inc has appointed Kurt Nielsen, PhD as chief technology officer and senior vice president, innovation and growth. Dr Nielsen will have responsibility for driving innovation activities and investments across Catalent’s broad range of advanced dose forms and packaging technologies.He will report to John Chiminski, president and CEO of Catalent, and will be based in the company’s global headquarters in Somerset, New Jersey, USA.
Dr Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical Company, where he led new product development and licensing activities for both products and drug delivery technologies, as well as the division’s manufacturing and quality operations. He previously held the position of vice president, research and development at URLMutual. Dr Nielsen also held prior research and development leadership positions with Teva Pharmaceuticals USA and the McNeil Consumer Products division of Johnson & Johnson. Dr Nielsen holds a PhD in Chemistry from Villanova University, and a Bachelor of Science in Chemistry from the University of Delaware.
Catalent Pharma Solutions is a provider of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer health care companies in almost 100 countries. The company employs about 9,300 people at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion of annual revenue.
- RSS Feed
